Obesity

Rx for Change: Polycystic Ovary Syndrome (PCOS)

By Charlea T. Massion, MD, and Adriane Fugh-Berman, MD | May 23, 2019 | Comments Off on Rx for Change: Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome (PCOS) is another name for “chronic oligoanovulation”—irregular or absent ovulation resulting in  irregular or absent menstruation. PCOS may be associated with ovaries that have multiple cysts; hyperandrogenism (increased DHEA and/or testosterone); excessive facial or body hair (hirsuitism); acne; and weight gain.

Obesity and Your Heart

By NWHN Staff | Feb 8, 2017 | Comments Off on Obesity and Your Heart

February is Heart Health Month! Did you know that heart disease is the number one killer of women?

Age, Weight, and My Sex Drive

By Shaniqua Seth | Jan 5, 2017 | Comments Off on Age, Weight, and My Sex Drive

A healthy sex life is crucial to many women and their partners. This can become more complicated with age and weight.

Making Healthy Choices About Nutrition

By Barbara Gold | Nov 12, 2016 | Comments Off on Making Healthy Choices About Nutrition

Like the old saying about the weather, everyone talks about nutrition but not much gets done about it. What we eat is tied so deeply to our cultures, our upbringing, our current lifestyles, and the political system we live under that changes seem daunting.

New Year, Same Old Miracle Drug Spin

By NWHN Staff | Jan 7, 2015 | Comments Off on New Year, Same Old Miracle Drug Spin

The holiday season is over and as usual, many people are feeling motivated to lose weight and live healthier. But for the one-third of Americans struggling with obesity, this struggle just gets harder and harder, especially as we age. For many, a safe and effective weight loss pill would seem like the magic bullet we so desperately need.

FDA Meeting – Qnexa Safety and Efficacy

By Kate Ryan | Feb 22, 2012 | Comments Off on FDA Meeting – Qnexa Safety and Efficacy

Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee Meeting

FDA Meeting – Naltrexone/Bupropion (Contrave)

By Kate Ryan | Dec 7, 2010 | Comments Off on FDA Meeting – Naltrexone/Bupropion (Contrave)

Food and Drug Administration (FDA) Gastroenterology Endocrinologic and Metabolic Drugs Advisory Committee